Rationale
With a significant number of “first generation,” blockbuster biopharmaceuticals either already, or soon to be, off-patent, Cantab Biopharmaceuticals Ltd (CBL) has positioned itself to exploit further development of previously marketed products to create high added value “Biosuperiors.”
CBL is identifying and assessing rational improvements to existing marketed products, licensing-in, or creating technology to address sub-optimal product characteristics and then utilise its experience in biological medicine development to expedite the biosuperior drug development pathway. Each product is being advanced to a significant point of value before being divested.